[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Stock Moves -0.43%: What You Should Know",
    "summary": "The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=7766d62b8ba047188f5a88de3865fcaaa339fd60ddd8b0dcf2e98316bcf28b85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741902315,
      "headline": "Pfizer (PFE) Stock Moves -0.43%: What You Should Know",
      "id": 133185261,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=7766d62b8ba047188f5a88de3865fcaaa339fd60ddd8b0dcf2e98316bcf28b85"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update",
    "summary": "NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.",
    "url": "https://finnhub.io/api/news?id=13eab334d24454b8591ca3795c909b8c6a9c59614762c9662690ac6eaaa91005",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741885500,
      "headline": "Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update",
      "id": 133185262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.",
      "url": "https://finnhub.io/api/news?id=13eab334d24454b8591ca3795c909b8c6a9c59614762c9662690ac6eaaa91005"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk",
    "summary": "AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=97963aec81445ff676b23871bfef68c04faaac987c94a9cb5d5b71726d72c61d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741881328,
      "headline": "AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk",
      "id": 133164007,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487502156/image_487502156.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=97963aec81445ff676b23871bfef68c04faaac987c94a9cb5d5b71726d72c61d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Says Chairman & CEO Albert Bourla's 2024 Total Compensation Was $24.6 Mln- SEC Filing",
    "summary": "Pfizer Inc: * PFIZER SAYS CHAIRMAN AND CEO ALBERT BOURLA'S 2024 TOTALCOMPENSATION WAS $24.6 MILLION- SEC FILINGSource text:Further company coverage:;)) ...",
    "url": "https://finnhub.io/api/news?id=a50a127d5088b9be3d7225deb43f597b1271b368331d0fe4c9d02f6756142b86",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741875481,
      "headline": "Pfizer Says Chairman & CEO Albert Bourla's 2024 Total Compensation Was $24.6 Mln- SEC Filing",
      "id": 133163510,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc: * PFIZER SAYS CHAIRMAN AND CEO ALBERT BOURLA'S 2024 TOTALCOMPENSATION WAS $24.6 MILLION- SEC FILINGSource text:Further company coverage:;)) ...",
      "url": "https://finnhub.io/api/news?id=a50a127d5088b9be3d7225deb43f597b1271b368331d0fe4c9d02f6756142b86"
    }
  },
  {
    "ts": null,
    "headline": "White House withdraws vaccine opponent Weldon for CDC director",
    "summary": "The White Housewithdrew President Donald Trump's nomination of formerRepublican congressman and vaccine critic Dave Weldon to serveas director of the U.S. Centers for Disease Control...",
    "url": "https://finnhub.io/api/news?id=9eb45f991c699cbf58b63c2b360ab00e013d839191fc93875c819a681effd5a8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741870618,
      "headline": "White House withdraws vaccine opponent Weldon for CDC director",
      "id": 133163220,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The White Housewithdrew President Donald Trump's nomination of formerRepublican congressman and vaccine critic Dave Weldon to serveas director of the U.S. Centers for Disease Control...",
      "url": "https://finnhub.io/api/news?id=9eb45f991c699cbf58b63c2b360ab00e013d839191fc93875c819a681effd5a8"
    }
  },
  {
    "ts": null,
    "headline": "This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year",
    "summary": "Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch.  Investors are, after all, paying a hefty premium for a business which still isn't generating any consistent revenue; its market capitalization remains north of $13 billion.  Hype and excitement around the potential for Summit's cancer treatment candidate, ivonescimab, has fueled the stock's rally.",
    "url": "https://finnhub.io/api/news?id=b6584c236fbdbb33c71da26602679fd17328920145e4a160547ef276fbdf7bee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741865400,
      "headline": "This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year",
      "id": 133185263,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch.  Investors are, after all, paying a hefty premium for a business which still isn't generating any consistent revenue; its market capitalization remains north of $13 billion.  Hype and excitement around the potential for Summit's cancer treatment candidate, ivonescimab, has fueled the stock's rally.",
      "url": "https://finnhub.io/api/news?id=b6584c236fbdbb33c71da26602679fd17328920145e4a160547ef276fbdf7bee"
    }
  }
]